Wall Street Zen Downgrades Mineralys Therapeutics (NASDAQ:MLYS) to Strong Sell

Mineralys Therapeutics (NASDAQ:MLYS) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday.

Several other brokerages have also issued reports on MLYS. Jefferies Financial Group reissued a “hold” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. HC Wainwright reaffirmed a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. Finally, TD Cowen started coverage on Mineralys Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating for the company. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Mineralys Therapeutics has an average rating of “Hold” and a consensus price target of $49.33.

Mineralys Therapeutics Price Performance

Mineralys Therapeutics stock opened at $25.64 on Friday. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of -6.05 and a beta of 0.68. The company’s 50 day simple moving average is $26.48 and its 200 day simple moving average is $27.50. The company has a debt-to-equity ratio of 0.18, a current ratio of 34.46 and a quick ratio of 34.46. Mineralys Therapeutics has a fifty-two week low of $14.16 and a fifty-two week high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its earnings results on Wednesday, August 12th. The company reported ($2.85) EPS for the quarter, missing the consensus estimate of ($0.55) by ($2.30). As a group, sell-side analysts anticipate that Mineralys Therapeutics will post -4.46 EPS for the current year.

Insider Activity at Mineralys Therapeutics

In other news, Director Daphne Karydas sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $25.00, for a total value of $75,000.00. Following the completion of the transaction, the director owned 6,200 shares in the company, valued at $155,000. This represents a 32.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Warren sold 104,124 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $25.90, for a total transaction of $2,696,811.60. Following the sale, the insider directly owned 38,400 shares of the company’s stock, valued at $994,560. This represents a 73.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 216,896 shares of company stock worth $5,613,000 over the last ninety days. 18.94% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Mineralys Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Navalign LLC acquired a new stake in shares of Mineralys Therapeutics in the 4th quarter valued at about $33,000. KBC Group NV acquired a new position in shares of Mineralys Therapeutics during the first quarter worth about $33,000. Royal Bank of Canada boosted its position in shares of Mineralys Therapeutics by 262.3% during the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock worth $56,000 after buying an additional 1,107 shares during the period. FNY Investment Advisers LLC grew its holdings in shares of Mineralys Therapeutics by 400.0% during the second quarter. FNY Investment Advisers LLC now owns 2,500 shares of the company’s stock worth $67,000 after buying an additional 2,000 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Mineralys Therapeutics by 1,845.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock worth $76,000 after buying an additional 1,993 shares in the last quarter. 84.46% of the stock is owned by institutional investors and hedge funds.

Key Mineralys Therapeutics News

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Near-term estimates improved: HC Wainwright raised its Q3 2026 EPS estimate to a loss of $0.56 from $0.61 and its Q4 estimate to a loss of $0.60 from $0.70. The firm maintained its Buy rating, indicating continued confidence in Mineralys’ prospects. Mineralys Therapeutics analyst coverage
• Positive Sentiment: Regulatory catalyst remains intact: Mineralys reiterated a December 22, 2026 PDUFA target date for lorundrostat, its investigational hypertension treatment, and said launch preparations are advancing. Approval could provide the company with its first commercial opportunity. Mineralys second-quarter results and corporate update
• Positive Sentiment: Cash runway and leadership support the launch plan: Management said its funding should support operations into 2028, while the appointment of Dr. Terry Ferguson as chief medical officer adds cardiovascular-development expertise ahead of a potential launch.
• Neutral Sentiment: Inducement awards granted to new CMO: Mineralys authorized options covering 135,000 shares and restricted stock units covering 102,400 shares for Dr. Ferguson. The awards help recruit key leadership but could modestly increase future share dilution. Mineralys inducement award announcement
• Negative Sentiment: Large quarterly earnings miss: Mineralys reported a second-quarter loss of $2.85 per share, far worse than the $0.55 consensus loss. The result highlights ongoing pre-commercial cash burn and likely contributes to investor caution.
• Negative Sentiment: Long-term earnings outlook was reduced: HC Wainwright cut its FY2026 EPS forecast to a loss of $4.47 from $2.33, FY2027 to a loss of $3.78 from $2.84, and FY2028 to a loss of $2.27 from $1.52. Its FY2029 profit estimate fell to $0.42 from $0.92, while FY2030 declined to $3.41 from $3.73. These revisions suggest profitability may take longer to develop.
• Negative Sentiment: Insider selling adds a modest negative signal: David Malcom Rodman sold 2,170 shares for approximately $58,785, reducing his stake by 4.05%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which limits its signaling value. Mineralys insider sale

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.